CATB - Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:
- H.C. Wainwright Global Life Sciences Conference. Presentations will be available on-demand from March 9-10, 2021.
- Oppenheimer 31 st Annual Healthcare Conference on Thursday, March 18, 2021 at 10:00am ET.
Webcasts of the events can be accessed from the investors section of www.catabasis.com . Archived replays will be available for 30 days following the event.
Catabasis is also participating in Guggenheim Healthcare Talks, 2021 Genomic Medicines & Rare Disease, on April 1, 2021.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005131/en/
Investor relations:
Andrea Matthews
investors@catabasis.com
Media:
Elizabeth Higgins
media@catabasis.com